| Name | Title | Contact Details |
|---|
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.
SyntheMed is a Iselin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AmMed Direct is a Antioch, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Osprey Medical is a medical device company incorporated in 2005 with operations based in Minnetonka, Minnesota, USA. The Company is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. Osprey Medical`s core technologies originated from research conducted by Dr. David Kaye at Melbourne`s Baker IDI Heart and Diabetes Institute
C. R. Bard is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialties. Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. Bard pioneered the development of single-patient-use medical products for hospital procedures; today Bard is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall health care costs.